课题基金 / 基金详情

Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)

Medicinal chemistry campaign to synthesize synaptamide analogs (GPR110)
合成突触酰胺类似物的药物化学活动(GPR110)
批准号:
10006287
负责人:
Juan Marugan
金额:
$25.03万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Juan Marugan的其他基金

相似基金

相关文献

中文摘要
翻译
在此期间,NCGC一直致力于合成新的突触他胺类似物,GPR110的测试开发正在进行中。 作为一个中心,NCGC与NIH和校外调查人员建立并保持了130多个积极的合作,促进了人类疾病整个谱系的药物发现工作。这些努力导致了数十个高通量筛选和许多药物化学活动,以进一步改进筛选命中,为我们的合作者和一般研究社区提供出版物和各种有前途的小分子探针和线索。此外,NCGC还致力于推进多项信息学倡议,以更好地利用现有的药物和疾病目标信息,并向公众提供易于获取的资源,进一步促进人类疾病新疗法的开发。
英文摘要
During this period, the NCGC has worked to synthesize novel analogues of synaptamide, and GPR110 assay development is ongoing. As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule agonists of the relaxin 1 receptor
Identification of Small Molecule that act on gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel
HTS Assay for Identification of Compounds that Reduce PNC Prevalence
海外基金